Short Bowel Syndrome Clinical Trial
Official title:
Plasma Determination of Glucagon-like Peptide 2 as a Predictor of Recovery in Adults With Acute Intestinal Failure
The purpose of this study is to investigate the theory that the plasma level of Glucagon like peptide 2 (GLP-2) in patients with intestinal failure can predict their clinical recovery.
When major segments of small bowel have been removed surgically, or damaged by disease, the
length of the residual bowel may be inadequate to maintain overall nutrition and the net
result is described as "intestinal failure".
Without medical intervention, patients with intestinal failure become malnourished and
dehydrated because their remaining intestine is unable to absorb enough water, vitamins and
other nutrients from the ingested food. Intravenous feeding offers life saving treatment but
causes complications like infections and liver problems. It also poses enormous strain on
day to day life.
Glucagon like peptide 2 (GLP-2) is a naturally occurring hormone (or chemical messenger)
that is able to increase the surface area of the intestinal lining (or mucosal mass) and the
absorptive efficiency of the remaining intestine.
Intestinal failure patients in whom not only parts of the small bowel but also the large
bowel have had to be surgically removed have been shown to have a markedly impaired rise in
GLP-2 levels following meals, in contrast to patients with a preserved large bowel who have
increased levels of GLP-2 and are known to have much better functional adaptation.
From this we hypothesise that the GLP-2 level is directly related to, and could predict,
clinical recovery in intestinal failure as measured by Amount of parenteral nutrition
required Length of hospital stay Mortality
We also aim to compare GLP-2 levels of patients with acute intestinal failure with that of
patients with chronic intestinal failure as well as healthy controls
;
Observational Model: Case Control, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT05635747 -
A 90 Day Observational Study as an Extension to the Phase 3,Open Labeled Exploratory Study of RELiZORB
|
||
| Completed |
NCT01891279 -
Elemental Formula in Neonates Post Small Bowel Resection: Improved Weaning From Total Parenteral Nutrition?
|
N/A | |
| Completed |
NCT00930644 -
Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS)
|
Phase 3 | |
| Completed |
NCT01696656 -
Prescription Pattern of Adjuvant Drugs and Vitamins in Patients Undergoing Long-term Home Nutritional Support for Intestinal Insufficiency
|
N/A | |
| Completed |
NCT00910104 -
Cholestasis Reversal: Efficacy of IV Fish Oil
|
Phase 2/Phase 3 | |
| Completed |
NCT04981262 -
Improved Quality of Life in Children With Intestinal Failure
|
N/A | |
| Completed |
NCT01930539 -
Treatment of Vitamin D Deficiency in Intestinal Rehabilitation Clinic Patients With a Portable Ultraviolet B Lamp
|
N/A | |
| Recruiting |
NCT05023382 -
A Study of Teduglutide in Japanese People With Short Bowel Syndrome
|
||
| Recruiting |
NCT04733066 -
Quality of Life in Patients With Short Bowel Syndrome Treated Without and With Teduglutide - a Prospective Nested Matched Pair Analysis
|
||
| Terminated |
NCT00742157 -
Evaluate the Efficacy and Safety Growth Hormone, Glutamine and Diet in Patients With Short Bowel Syndrome (SBS)
|
Phase 4 | |
| Completed |
NCT04743960 -
Assessing Metabolic and Sleep Consequences of Overnight Home Parenteral Nutrition
|
N/A | |
| Completed |
NCT03690206 -
Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)
|
Phase 3 | |
| Terminated |
NCT02266849 -
Loperamide vs. Placebo's Effect on Ileostomy Output: A Clinical Randomized Blinded Cross-over Study
|
Phase 3 | |
| Completed |
NCT01306838 -
Early Provision of Enteral Microlipid and Fish Oil to Infants With Enterostomy
|
Early Phase 1 | |
| Completed |
NCT01380366 -
rHGH and Intestinal Permeability in Intestinal Failure
|
Phase 4 | |
| Completed |
NCT00248573 -
Mechanisms of Adaptation in Human Short Bowel Syndrome
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT03371862 -
Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS)
|
Phase 2 | |
| Completed |
NCT04474743 -
Malnutrition in Chronic Gastrointestinal Diseases, Cross-sectional Study
|
||
| Completed |
NCT00067860 -
Diet/Growth Factor Mechanisms of Gut Adaptation
|
Phase 2 | |
| Terminated |
NCT04046328 -
Efficacy, Safety and Tolerability of Enteric-Coated Cholestyramine Capsules for Adult Short Bowel Syndrome
|
Phase 2 |